Description
Anti-ITGAV Antibody, Highly Galactosylated (BioBet-GA-332ZP) is a humanized IgG2, κ antibody against ITGAV which contains with a high level of galactosylation.
Antibody Indication
Colorectal cancers, metastatic
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ITGAV antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Integrin Subunit Alpha V
Background
The product of this gene belongs to the integrin alpha chain family. Integrins are heterodimeric integral membrane proteins composed of an alpha subunit and a beta subunit that function in cell surface adhesion and signaling. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin may regulate angiogenesis and cancer progression. Alternative splicing results in multiple transcript variants. Note that the integrin alpha 5 and integrin alpha V subunits are encoded by distinct genes. [provided by RefSeq, Oct 2015]
Alternative Names
Abituzumab; 1105038-73-0; EMD525797; EMD 525797; DI-17E6; DI17E6; ITGAV; integrin, alpha V; antigen identified by monoclonal L230, integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51), MSK8, vitronectin receptor, VNRA, VTNR;
Cellular Localization
Plasma membrane
Involvement in Disease
Its related pathways are Integrin Pathway and Signaling by GPCR.
Related Pathways
Integrins are receptors for vitronectin, cytoactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, and vWF. They can recognize R-G-D sequences in a large number of ligands. ITGAV: ITGB3 binds to fractalkine (CX3CL1) and may act as its co-receptor in cx3cr1-dependent fractalkine signaling. ITGAV: ITGB3 binds to NRG1 (via the EGF domain), and this combination is essential for NRG1-erbb signaling. ITGAV: ITGB3 binds to FGF1, and this combination is essential for FGF1 signal transduction. ITGAV: ITGB3 binds to FGF2, and this combination is essential for FGF2 signaling. ITGAV: ITGB3 binds to IGF1, and this combination is essential for IGF1 signaling. ITGAV: ITGB3 combines with IGF2, and this combination is essential for IGF2 signaling. ITGAV: ITGB3 binds to IL1B, and this combination is essential for IL1B signaling. ITGAV: ITGB3 binds to PLA2G2A through a site (2) different from the classical ligand binding site (1), thereby inducing a change in the conformation of the integrin and enhancing the binding of the ligand to site 1. TGAV:ITGB3 and ITGAV:ITGB6 act as receptors for fibrillin 1 (FBN1) and mediate r-g -d dependent cell adhesion to FBN1. Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates r-g-d-dependent release of transforming growth factor-1 ( tgf -1), thus playing a key role in the activation of tgf -1. ITGAV: ITGB3 acts as a receptor for CD40LG.
Field of research
1.Glycosylation at Asn74, Asn290, Asn296, Asn488, Asn554, Asn615, Asn704, Asn835, Asn851, Asn874, Asn945, Asn973, and Asn980 2.Ubiquitination at Lys233 and Lys360 3.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-GA-332ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human ITGAV. Abituzumab (EMD 525797)is a humanised monoclonal antibody targeting integrin αν heterodimers.
Antibody Indication
Colorectal cancers, metastatic
